Navigation Links
Verenium Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., Oct. 5 /PRNewswire-FirstCall/ -- Verenium Corporation (Nasdaq: VRNMD), a pioneer in the development of next-generation cellulosic ethanol and high-performance specialty enzymes, today announced that it intends to offer, subject to market, regulatory and other conditions, shares of its common stock, and potentially warrants, in an underwritten public offering. The offering is expected to price before 9:30 am EDT on Tuesday, October 6, 2009. Lazard Capital Markets LLC is acting as the sole book-running manager for the offering.

The securities described above are being offered by the Company pursuant to a shelf registration statement which was filed with the Securities and Exchange Commission (SEC) and became effective on January 14, 2008. A prospectus supplement describing the terms of this offering will be filed with the SEC and forms part of the effective Registration Statement.

When available, copies of the final prospectus supplement and accompanying base prospectus relating to this offering can be obtained at the SEC's website at or from Lazard Capital Markets LLC at 30 Rockefeller Plaza, 60th Floor, New York, NY 10020.

This press release is not an offer to sell or the solicitation of an offer to buy these securities, nor shall it constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

About Verenium

Verenium Corporation is a leader in the development and commercialization of cellulosic ethanol, an environmentally-friendly and renewable transportation fuel, as well as high-performance specialty enzymes for applications within the biofuels, industrial, and animal health markets. The Company possesses integrated, end-to-end capabilities and cutting-edge technology in pre-treatment, novel enzyme development, fermentation and project development for next-generation biofuels. Through Vercipia, the Company is moving rapidly to commercialize cellulosic technology for the production of ethanol from a wide array of non-food feedstocks, including dedicated energy crops, agricultural waste, and wood products. In addition to the vast potential for biofuels, a multitude of large-scale industrial opportunities exist for the Company for products derived from the production of low-cost, biomass-derived sugars.

Verenium's Specialty Enzyme business harnesses the power of enzymes to create a broad range of specialty products to meet high-value commercial needs. Verenium's world class R&D organization is renowned for its capabilities in the rapid screening, identification, and expression of enzymes-proteins that act as the catalysts of biochemical reactions. For more information on Verenium, visit

Forward Looking Statements

Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty. These include, but are not limited to, statements related to the Company's expectations regarding its fund raising efforts, including the closing of the current public offering, its financial condition, operations, capabilities, commercialization activities, and future financial performance, results and objectives, all of which are prospective. Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with the costs, labor requirements and labor availability associated with operating its business, including ethanol production, and risks and other uncertainties more fully described in the Company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's annual report on Form 10-K for the year ended December 31, 2008 and any updates contained in its subsequently filed quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any intent or obligation to update these forward-looking statements.


    Kelly Lindenboom                  Sarah Carmody
    Vice President, Corporate         Sr. Corporate Communications Associate
    617-674-5335                      617-674-5357

SOURCE Verenium Corporation

SOURCE Verenium Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
2. Verenium Advances Its Development Work With Cargill on a New Food-Related Product
3. Verenium Corporation to Present at the Pacific Growth Equities 2007 Clean Technology & Industrial Growth Conference
4. Verenium Explores Bacterial Genes Inside Termite Guts to Understand How Wood is Broken Down and Converted to Energy
5. Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference
6. Verenium Reports Financial Results for the First Quarter 2008
7. Verenium Appoints John F. Dee to Board of Directors
8. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
9. Verenium Corporation to Present at the William Blair & Company 2008 Small-Cap Growth Stock Conference
10. Verenium Corporation to Announce Third Quarter 2008 Financial Results
11. Verenium Corporation to Speak at the Credit Suisse Alternative Energy Conference
Post Your Comments:
(Date:10/8/2015)... 2015  Sigma-Aldrich Corporation (NASDAQ: SIAL ) ... within its Applied Diagnostics and Testing business segment ... product line with ten certified Snap-N-Spike ® ... and their stable-labeled internal standards. These new solution ... taurocholic acid and native and deuterium-labeled analogs of ...
(Date:10/7/2015)... India , October 8, 2015 /PRNewswire/ ... --> Medical biotechnology accounts for largest ... of bioinformatics in drug discovery and development ... . ... On the basis of applications, the ...
(Date:10/7/2015)... , Oct. 7, 2015  ChromaDex Corp. (OTCQX: ... nutritional ingredients that creates science-based solutions for dietary ... and pharmaceutical products, today announced that the October ... and Founder, is now available for on-demand viewing ... -->   --> ...
(Date:10/7/2015)... RADNOR, Pa. , Oct. 7, 2015   ... global, independent provider of laboratory products, services and ... Technologies Inc. (PTI), a specialty solvent company that ... solvents. This acquisition will enhance VWR,s growing laboratory ... its laboratory and biopharmaceutical manufacturing customers. ...
Breaking Biology Technology:
... JOLLA, Calif., Oct. 20, 2011 Regulus Therapeutics ... development of innovative medicines targeting microRNAs, and collaborators at ... Center today announced the publication of new pre-clinical research ... et al., Nature , October 20, 2011). ...
... cell carcinomas are amongst the most frequent cancers in ... like many other human cancers, contain particular cancer cells, ... potential that sustain tumor growth. Little is known about ... High level of VEGF expression in skin cancer ...
... Researchers at Purdue University and the National Institute of ... enough to fit on a computer chip that converts ... that might have applications in more advanced sensors, communications ... very high rates, corresponding to hundreds of billions of ...
Cached Biology Technology:
(Date:9/30/2015)... Calif. , Sept. 30, 2015  With nearly ... the number of new SCIs estimated to reach 12,500 ... Southern California Resource Services for Independent Living ... ILCs in California opening doors ... range of programs and services, notably assistive technology services ...
(Date:9/29/2015)... Sept. 29, 2015 News facts: ... while also saving energy , Minimized design shrinks ... Power Active Mode and embedded Fujitsu PalmSecure authentication enable ... Fujitsu today shows that good things come in ... models to its enterprise desktop and mobile portfolio. Featuring ...
(Date:9/28/2015)...  The monitoring of vital signs, such as ... an essential component of patient assessment. Changes in ... a patient,s condition. However, in general care areas ... during routine observation rounds only once every four ... these observation rounds, the warning signs can go ...
Breaking Biology News(10 mins):
... popular with consumers who like the convenience and ... table grapes fresh and increase shelf life, scientists ... alternatives to conventional packing methods. Researchers from the ... ARS) have developed and tested an effective new ...
... OHLoblolly pine bark is the primary component of nursery ... shortage of the widely used organic material is prompting ... recent study by James E. Altland and Charles Krause ... Agricultural Research and Development Center was designed to determine ...
... within patient records or detailed in newspaper clippings can ... the discovery of trends that were previously overlooked, according ... interactive maps and graphs, combined with word search interfaces, ... the spread of Swine flu," said Frank Hardisty, research ...
Cached Biology News:
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
Anti-Dardarin Immunogen: Synthetic peptide from rat LRRK2. Available Date: 38814...
Mouse monoclonal [15-2] to Mannose Receptor (Biotin) ( Abpromise for all tested applications). entrezGeneID: 4360 SwissProtID: P22897...
Purified Mouse anti-Hu LAT (pY226) Storage Temperature: Refrigerate(2 to 8C)...
Biology Products: